ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to clinical trial diversity; Issues related to workforce development; Issues related to the biopharmaceutical supply chain; Pandemic and All-Hazards Preparedness Reauthorization; General issues related to rare disease and orphan drugs; FDA modernization policy issues; Reauthorization of newborn screening programs; General issues related to health equity in rare disease and clinical trials; General issues related to diagnostics for patients with rare diseases; Issues related to rare disease patients with employer sponsored insurance; 340b reform; Sustainability; Discussions with USG (BARDA/HHS team) to discuss possible contracts; Issues related to Agriculture, Rural Development, and Food & Drug Administration appropriations; Issues related to the Labor, Health and Human Services, and Education appropriations; Medicare Part D; Medicare Part B; Medicare oncology populations; Drug Pricing, including H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act (117th Congress); H.R. 1503, Prescription Information Modernization Act of 2023; H.R. 1613, Drug Pricing Transparency in Medicaid Act of 2023; Issues related to implementation of H.R.5376 - Inflation Reduction Act of 2022 (Public Law No. 117-169); Issues related to the orphan drug exclusion of the Inflation Reduction Act; Specific focus on drug negotiation (orphan drug exemption language), Medicare Part D reform, and inflation penalties; H.R. 2407, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; Issues related to lung cancer screening. Issues related to Pharmacy Benefit Managers (PBMs), including S. 127, Pharmacy Benefit Manager Transparency Act of 2023; S. 113, Prescription Pricing for the People Act of 2023.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CUDWORTH ARBES | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Medicare/Medicaid MMM
CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure; Centers for Medicare and Medicaid Innovation (CMMI) policy issues; Issues pertaining to implementation of the Inflation Reduction Act,H.R.5376 - Inflation Reduction Act of 2022 (Public Law No. 117-169); Medicare patient access to rare disease therapies, Part B and Part D drugs; Value-based payment arrangements; efforts to improve coding, coverage, and access for rare disease therapies; Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies; General issues related to diagnostic reimbursement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CUDWORTH ARBES | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Pharmacy PHA
Issues pertaining to pharmacy benefit management (PBM) reform, including S. 127, the Pharmacy Benefit Manager Transparency Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CUDWORTH ARBES | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Taxation/Internal Revenue Code TAX
Section 174 R&D Amortization; International tax issues; Issues related to the Orphan Drug Tax Credit; Issues related to the deduction of research and development expenditures; H.R. 1350, Camerons Law.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CUDWORTH ARBES | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Budget/Appropriations BUD
Issues related to Agriculture, Rural Development, and Food & Drug Administration appropriations; Issues related to the Labor, Health and Human Services, and Education appropriations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CUDWORTH ARBES | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Copyright/Patent/Trademark CPT
S. 142, Preserving Access to Affordable Generics and Biosimilars Act; S. 150, Affordable Prescriptions for Patients Act of 2023; Pharmaceutical IP Patent Reform TRIPS waiver
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CUDWORTH ARBES | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Insurance INS
Pharmacy Benefit Managers (PBM) reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HELEN DWIGHT | — |
| KATIE JONES | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.